EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

An oncogenic CTNNB1 mutation is predictive of post-operative recurrence-free survival in an EGFR-mutant lung adenocarcinoma

Yeseul Kim iD, Bokyung Ahn iD, Shinkyo Yoon, Goeun Lee, Deokhoon Kim, Sung-Min Chun, Hyeong-Ryul Kim, Se Jin Jang, Hee Sang Hwang iD

PLOS ONE · 2023

DOI: 10.1371/journal.pone.0287256 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS ONE, 2023. Verfasst von Yeseul Kim und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Korea University College of Medicine, Korea University Anam Hospital, Seoul, Republic of Korea. Hauptthemen laut MEDLINE: Adenocarcinoma of Lung, Adenocarcinoma, Lung Neoplasms. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Research Foundation of Korea.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The Wnt/β-catenin pathway is known to be frequently dysregulated in various human malignancies. Alterations in the genes encoding the components of Wnt/β-catenin pathway have also been described in lung adenocarcinoma. Notably however, the clinical impacts of Wnt/β-catenin pathway alterations in lung adenocarcinoma have not been fully evaluated to date. We here investigated the prognostic implications of single gene variations in 174 cases of surgically resected lung adenocarcinoma tested using targeted next-generation sequencing. Screening of the prognostic impact of single gene alterations identified an association between CTNNB1 mutation and poor recurrence-free survival in EGFR -mutant LUADs. Based on these results, the entire cohort was stratified into three groups in accordance with the mutational status of Wnt/β-catenin pathway genes (i.e. oncogenic CTNNB1 mutation [ CTNNB1 -ONC], other Wnt/β-catenin pathway gene mutations [Wnt/β-catenin-OTHER], and wild type for Wnt/β-catenin pathway genes [Wnt/β-catenin-WT]). The clinicopathologic characteristics and survival outcomes of these groups were then compared. Oncogenic CTNNB1 and other Wnt/β-catenin pathway gene mutations were identified in 10 (5.7%) and 14 cases (8.0%), respectively. The CTNNB1 -ONC group cases displayed histopathologic features of conventional non-mucinous adenocarcinoma with no significant differences from those of the other groups. Using β-catenin immunohistochemistry, we found that the CTNNB1 -ONC group displayed aberrant nuclear staining more frequently, but only in 60% of the samples. The LUADs harboring a CTNNB1 -ONC exhibited significantly poorer RFS outcomes than the other groups, regardless of the β-catenin IHC status. This was a pronounced finding in the EGFR -mutant LUADs only in subgroup analysis, which was then confirmed by multivariate analysis. Nevertheless, no significant OS differences between these Wnt/β-catenin groups were evident. Hence, oncogenic CTNNB1 mutations may be found in about 6% of lung adenocarcinomas and may predict post-operative recurrence in EGFR -mutant LUADs. Aberrant nuclear β-catenin staining on IHC appears to be insufficient as a surrogate marker of an oncogenic CTNNB1 mutation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Adenocarcinoma of LungAdenocarcinomaLung NeoplasmsHumansbeta CateninMutationErbB ReceptorsDNA Mutational Analysis

Substanzen

beta CateninErbB ReceptorsCTNNB1 protein, humanEGFR protein, human

Autor:innen und Institutionen

  • Department of Pathology, Korea University College of Medicine, Korea University Anam Hospital, Seoul, Republic of Korea.
  • Department of Pathology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Republic of Korea.
  • Department of Oncology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Republic of Korea.
  • Department of Thoracic and Cardiovascular Surgery, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Republic of Korea.

ORCID-Profile: Yeseul Kim, Bokyung Ahn, Hee Sang Hwang

Förderung

  • National Research Foundation of Korea

Zitieren

APA

Kim, Y., Ahn, B., Yoon, S., Lee, G., Kim, D., Chun, S. M., Kim, H. R., Jang, S. J., & Hwang, H. S. (2023). An oncogenic CTNNB1 mutation is predictive of post-operative recurrence-free survival in an EGFR-mutant lung adenocarcinoma. PLOS ONE. https://doi.org/10.1371/journal.pone.0287256

Vancouver

Kim Y, Ahn B, Yoon S, Lee G, Kim D, Chun SM, et al. An oncogenic CTNNB1 mutation is predictive of post-operative recurrence-free survival in an EGFR-mutant lung adenocarcinoma. PLOS ONE. 2023. doi:10.1371/journal.pone.0287256

BibTeX
@article{Kim2023,
  author = {Kim, Yeseul and Ahn, Bokyung and Yoon, Shinkyo and Lee, Goeun and Kim, Deokhoon and Chun, Sung-Min and Kim, Hyeong-Ryul and Jang, Se Jin and Hwang, Hee Sang},
  title = {An oncogenic CTNNB1 mutation is predictive of post-operative recurrence-free survival in an EGFR-mutant lung adenocarcinoma},
  journal = {PLOS ONE},
  year = {2023},
  doi = {10.1371/journal.pone.0287256}
}
Kostenlos starten →